HSK GeneTech

HSK GeneTech is a clinical-stage biotechnology company specializing in the development of adeno-associated virus (AAV) mediated gene therapies for rare genetic disorders. As a subsidiary of Sichuan Haisco Pharmaceutical Group, the company leverages a proprietary AAV platform to design and manufacture high-potency genetic medicines. Their lead candidate, HSK34890, is currently undergoing clinical evaluation for the treatment of Hemophilia B, aiming to provide a durable therapeutic effect through a single administration. The company's pipeline also includes programs for Hemophilia A and other metabolic diseases. HSK GeneTech is committed to establishing a full-value chain capability in gene therapy, from early-stage discovery to GMP-compliant manufacturing.